Retrospective Cohort Study
Copyright ©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Sep 15, 2020; 12(9): 992-1004
Published online Sep 15, 2020. doi: 10.4251/wjgo.v12.i9.992
Prognostic significance of Borrmann type combined with vessel invasion status in advanced gastric cancer
Zhao Zhai, Zi-Yu Zhu, Yu Zhang, Xin Yin, Bang-Ling Han, Jia-Liang Gao, Sheng-Han Lou, Tian-Yi Fang, Yi-Min Wang, Chun-Feng Li, Xue-Feng Yu, Yan Ma, Ying-Wei Xue
Zhao Zhai, Zi-Yu Zhu, Yu Zhang, Xin Yin, Bang-Ling Han, Jia-Liang Gao, Sheng-Han Lou, Tian-Yi Fang, Yi-Min Wang, Chun-Feng Li, Xue-Feng Yu, Yan Ma, Ying-Wei Xue, Department of Gastroenterological Surgery, Harbin Medical University Cancer Hospital, Harbin 150081, Heilongjiang Province, China
Author contributions: Zhai Z and Zhu ZY designed the research and study concept; Han BL performed the research and data collection; Gao JL, Yin X, and Zhang Y performed the statistical analysis; Lou SH, Fang TY, Wang YM, Li CF, Yu XF, and Ma Y performed the data interpretation; Zhai Z drafted the manuscript; Xue YW revised the manuscript.
Supported by Nn10 Program of Harbin Medical University Cancer Hospital, China, No. Nn10 PY 2017-03.
Institutional review board statement: The study was approved by the Ethics Committee of the Affiliated Tumor Hospital of Harbin Medical University.
Informed consent statement: All study participants or their legal guardian provided informed written consent about personal and medical data collection prior to study enrolment.
Conflict-of-interest statement: All the authors have no conflict of interest related to the manuscript.
Data sharing statement: The original anonymous dataset is available on request from the corresponding author at xueyingwei@hrbmu.edu.cn.
STROBE statement: The authors have read the STROBE Statement—checklist of items, and the manuscript was prepared and revised according to the STROBE Statement—checklist of items.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Ying-Wei Xue, PhD, Chief Doctor, Department of Gastroenterological Surgery, Harbin Medical University Cancer Hospital, No. 150 Haping Road, Harbin 150081, Heilongjiang Province, China. xueyingwei@hrbmu.edu.cn
Received: June 15, 2020
Peer-review started: June 15, 2020
First decision: July 30, 2020
Revised: August 11, 2020
Accepted: August 31, 2020
Article in press: August 31, 2020
Published online: September 15, 2020
Processing time: 86 Days and 16.5 Hours
ARTICLE HIGHLIGHTS
Research background

Gastric cancer (GC) is an important public health burden worldwide. Although the evolution of diagnostic methods has led to an increase in the diagnosis rate of early gastric cancer, most patients present with an advanced stage when they are diagnosed with gastric cancer. Comprehensive multimodal and multidisciplinary treatment systems, including chemotherapy and targeted therapy, are gradually improving. Many studies have shown that Borrmann type and lymphatic and/or blood vessel invasion (LBVI) are independent risk factors for the prognosis of patients with advanced gastric cancer, but few studies have analyzed the prognostic significance of the combination of the two indexes in patients with advanced gastric cancer.

Research motivation

Analyzing whether Borrmann type combined with LBVI has prognostic significance for advanced gastric cancer will provide a basis for clinicians to treat and predict the prognosis of these patients in the future.

Research objectives

To evaluate the significance of Borrmann type combined with LBVI status in evaluating the prognosis of advanced gastric cancer.

Research methods

This retrospective study analyzed the clinicopathological characteristics and long-term survival data of 2604 patients with advanced gastric cancer, all of whom were diagnosed with advanced gastric adenocarcinoma at the Affiliated Tumor Hospital of Harbin Medical University from 2009 to 2013. Categorical variables were evaluated by the Pearson’s χ2 test, the Kaplan-Meier method was used to identify differences in cumulative survival rates, and the Cox proportional hazards model was used for multivariate prognostic analysis.

Research results

This retrospective study included a total of 2604 patients. The results showed that the 5-year survival rate of Borrmann types I-IV patients was significantly different (P < 0.001), and the 5-year survival rate of patients with LBVI (+) was significantly lower than that of LBVI (-) patients. When we combined Borrmann type and LBVI status, we found that patients with Borrmann type III disease and LBVI (+) had a similar 5-year survival rate to those with Borrmann type IV disease and LBVI (-) (16.4% vs 13.1%, P = 0.065) or LBVI (+) (16.4% vs 11.2%, P = 0.112). Subgroup analysis showed that the above results were true in any pT stage and any tumor location. Multivariate Cox regression analysis showed that Borrmann type (P = 0.023), LBVI (P < 0.001), tumor size (P = 0.012), pT staging (P < 0.001), pN stage (P < 0.001), and extent of radical surgery (P < 0.001) are independent prognostic factors.

Research conclusions

Borrmann type, LBVI status, tumor size, pT stage, pN stage, and extent of radical surgery all independently affect prognosis. Patients with Borrmann type III disease and LBVI (+) have a similar 5-year survival rate to those with Borrmann type IV disease and LBVI (-) or LBVI (+)

Research perspectives

We recommend that clinicians should formulate a comprehensive multidisciplinary, multimodal, and individualized treatment plan when they encounter patients with Borrmann type III GC and LBVI (+), regardless of the pT stage and tumor location, to obtain better survival results.